BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28934959)

  • 1. Selective inhibition of PfA-M1, over PfA-M17, by an amino-benzosuberone derivative blocks malaria parasites development in vitro and in vivo.
    Bounaadja L; Schmitt M; Albrecht S; Mouray E; Tarnus C; Florent I
    Malar J; 2017 Sep; 16(1):382. PubMed ID: 28934959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
    Drinkwater N; Vinh NB; Mistry SN; Bamert RS; Ruggeri C; Holleran JP; Loganathan S; Paiardini A; Charman SA; Powell AK; Avery VM; McGowan S; Scammells PJ
    Eur J Med Chem; 2016 Mar; 110():43-64. PubMed ID: 26807544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
    Chaudhary M; Singh V; Anvikar AR; Sahi S
    Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18.
    Paiardini A; Bamert RS; Kannan-Sivaraman K; Drinkwater N; Mistry SN; Scammells PJ; McGowan S
    PLoS One; 2015; 10(2):e0115859. PubMed ID: 25700165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X-ray crystal structures of an orally available aminopeptidase inhibitor, Tosedostat, bound to anti-malarial drug targets PfA-M1 and PfA-M17.
    Drinkwater N; Bamert RS; Sivaraman KK; Paiardini A; McGowan S
    Proteins; 2015 Apr; 83(4):789-95. PubMed ID: 25645579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
    González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
    Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases.
    McGowan S; Oellig CA; Birru WA; Caradoc-Davies TT; Stack CM; Lowther J; Skinner-Adams T; Mucha A; Kafarski P; Grembecka J; Trenholme KR; Buckle AM; Gardiner DL; Dalton JP; Whisstock JC
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2449-54. PubMed ID: 20133789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.
    Mistry SN; Drinkwater N; Ruggeri C; Sivaraman KK; Loganathan S; Fletcher S; Drag M; Paiardini A; Avery VM; Scammells PJ; McGowan S
    J Med Chem; 2014 Nov; 57(21):9168-83. PubMed ID: 25299353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening.
    Ruggeri C; Drinkwater N; Sivaraman KK; Bamert RS; McGowan S; Paiardini A
    PLoS One; 2015; 10(9):e0138957. PubMed ID: 26406322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and chemical validation of
    Edgar RCS; Siddiqui G; Hjerrild K; Malcolm TR; Vinh NB; Webb CT; Holmes C; MacRaild CA; Chernih HC; Suen WW; Counihan NA; Creek DJ; Scammells PJ; McGowan S; de Koning-Ward TF
    Elife; 2022 Sep; 11():. PubMed ID: 36097817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1'-region optimisation.
    Calic PPS; Vinh NB; Webb CT; Malcolm TR; Ngo A; Lowes K; Drinkwater N; McGowan S; Scammells PJ
    Eur J Med Chem; 2023 Feb; 248():115051. PubMed ID: 36634455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.
    Skinner-Adams TS; Stack CM; Trenholme KR; Brown CL; Grembecka J; Lowther J; Mucha A; Drag M; Kafarski P; McGowan S; Whisstock JC; Gardiner DL; Dalton JP
    Trends Biochem Sci; 2010 Jan; 35(1):53-61. PubMed ID: 19796954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
    Cunningham E; Drag M; Kafarski P; Bell A
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3221-8. PubMed ID: 18458130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling of human leucyl aminopeptidases for in silico off target binding analysis of potential Plasmodium falciparum leucine aminopeptidase (PfA-M17) specific inhibitors.
    Sahi S; Raj U; Chaudhary M; Nain V
    Recent Pat Endocr Metab Immune Drug Discov; 2014; 8(3):191-201. PubMed ID: 25269653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminobenzosuberone derivatives as PfA-M1 inhibitors: Molecular recognition and antiplasmodial evaluation.
    Salomon E; Schmitt M; Mouray E; McEwen AG; Bounaadja L; Torchy M; Poussin-Courmontagne P; Alavi S; Tarnus C; Cavarelli J; Florent I; Albrecht S
    Bioorg Chem; 2020 May; 98():103750. PubMed ID: 32182520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG antibody response against Plasmodium falciparum aminopeptidase 1 antigen in Gabonese children living in Makokou and Franceville.
    Oyegue-Liabagui SL; Imboumy-Limoukou RK; Kouna CL; Bangueboussa F; Schmitt M; Florent I; Lekana-Douki JB
    Clin Exp Immunol; 2020 Jun; 200(3):287-298. PubMed ID: 32027020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents.
    Flipo M; Beghyn T; Leroux V; Florent I; Deprez BP; Deprez-Poulain RF
    J Med Chem; 2007 Mar; 50(6):1322-34. PubMed ID: 17326615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the substrate specificity of the Plasmodium M1 and M17 aminopeptidases.
    Malcolm TR; Swiderska KW; Hayes BK; Webb CT; Drag M; Drinkwater N; McGowan S
    Biochem J; 2021 Jul; 478(13):2697-2713. PubMed ID: 34133730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.
    Edgar RCS; Malcolm TR; Siddiqui G; Giannangelo C; Counihan NA; Challis M; Duffy S; Chowdhury M; Marfurt J; Dans M; Wirjanata G; Noviyanti R; Daware K; Suraweera CD; Price RN; Wittlin S; Avery VM; Drinkwater N; Charman SA; Creek DJ; de Koning-Ward TF; Scammells PJ; McGowan S
    mBio; 2024 Jun; 15(6):e0096624. PubMed ID: 38717141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
    Vinh NB; Drinkwater N; Malcolm TR; Kassiou M; Lucantoni L; Grin PM; Butler GS; Duffy S; Overall CM; Avery VM; Scammells PJ; McGowan S
    J Med Chem; 2019 Jan; 62(2):622-640. PubMed ID: 30537832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.